NCT04038710View on ClinicalTrials.gov

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

February 26, 2021

Study Completion Date

February 26, 2021

Conditions
Cystic Fibrosis
Interventions
DRUG

Triple combination therapy

Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
lead

National Jewish Health

OTHER

NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease. | Biotech Hunter | Biotech Hunter